u/joaquin_stanescu

Kept a spreadsheet of quoted versus actual across a year. The quote held; the variance was all in the last mile.

no tracking numbers, ever

SELECT was cardiovascular outcomes, not weight

Same. SSA quoted 11 days on my lane and it landed at 13, which is exactly what you want from a quote.

Same lane in a different season for comparison?

Careful. A four-week stall is inside normal variation and treating it as failure is how people escalate for no reason.

Steady state after a dose change takes four to five half-lives, so the fair judgement point on a new step is about a month, not four days.

food noise made the first fortnight rough at each step up, then flattened out. Predictable enough that I started planning around it.

Regional stock replaces an international lane with a domestic one. That is a structural change to the distribution, not a marginal improvement, and it is why the warehouse question matters more than the carrier question.

check who the comparator was before you compare anything

Research-use-only material is not approved for human use, so anything in this thread about how a compounded or research vial "should" behave is a chemistry discussion, not a dosing one.

What does time in range look like, not just the average?

Small correction: 2.4mg is the maintenance ceiling on the label, not the starting maintenance dose.

Right, and the timescale is the bit that keeps getting lost. Judge a step at a month, not at a weekend.

a mean is not a promise

Small fix — shipped from the regional warehouse, not from origin, which is why the number looks unusual.

What was the packaging like on arrival?

rigid outer packaging is the cheapest quality signal there is

a mean is not a promise

Steady state after a dose change takes four to five half-lives, so the fair judgement point on a new step is about a month, not four days.

rigid outer packaging is the cheapest quality signal there is

Certain conditions affect A1c independently of glycaemia. If a result looks inconsistent with the sensor data, that is a question for whoever manages your care rather than for this board.

Started keeping the trial identifiers straight in a note file because I kept mixing up two programmes in the same sentence.

Is that intention-to-treat or completers?

Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about.

The registered protocol is public. Comparing the registered primary endpoint with the reported one is a two-minute check and it is how outcome switching gets caught.

no tracking numbers, ever

Yes — regional stock is the single biggest variable and it barely gets mentioned outside this board.

Steady state after a dose change takes four to five half-lives, so the fair judgement point on a new step is about a month, not four days.

Four observations is not a distribution. The lane tables here only became predictive once individual routes had a dozen or more reports behind them.

dose day drift of a day either way is fine, the curve barely notices

That A1c change is inside the assay’s variability and the interval you measured over is too short.

Cosigning.

This is the part I would underline for anyone skimming. Everything else in the thread is downstream of it.

Same. I sat at 1.7mg for three months because it was working and there was nothing to fix.

SELECT was cardiovascular outcomes, not weight

STEP-1 averaged just under 15% at 68 weeks, so a 10% year is not a failure

postprandial excursions are where most of the improvement shows up first

A quoted lead time is a commitment you can evaluate. Measuring quoted against actual across several orders tells you more about an operation than the raw speed does.